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We report data regarding kinetic of response to oral iron in 34 iron deficiency anemia children. Twenty-four/34 patients (70.5%)
reached reference value of hemoglobin (Hb) concentration for age and sex at day + 30 from the beginning of treatment (complete
early responders (CERs)), and 4/34 (12%) reached anHb concentration at least 50%higher than the original (partial early responders
(PERs)). CHr at T1 (within 7 days from the beginning of treatment) was significantly different in the different groups (22.95 in CERs
versus 18.41 in other patients; 𝑝 = 0.001; 22.42 in early responders versus 18.07 in NERs; 𝑝 = 0.001). Relative increase of CHr from
T0 to T1 resulted significantly higher in CERs than in other patients (0.21 versus 0.11, 𝑝 = 0.042) and in early responders than in
NERs (0.22 versus 0.004, 𝑝 = 0.006). Multivariate logistic models revealed a higher probability of being a complete early responder
due to relative increase of ARC fromT0 to T1 [OR (95%CI) = 44.95 (1.54–1311.98)] and toCHr at T1 [OR (95%CI) =3.18 (1.24–8.17)].
Our preliminary data confirm CHr as early and accurate predictor of hematological response to oral iron.
1. Introduction
Reticulocytes are the youngest erythrocytes released from
the bone marrow into circulating blood. Under normal
conditions, after maturing for 1–3 days within the bone
marrow, they are released into peripheral blood where they
circulate for 1-2 days before becoming mature erythrocytes.
The reticulocyte hemoglobin content (CHr) provides an
indirect measure of the functional iron available for new red
blood cell production over the previous 3-4 days [1]. CHr
in peripheral blood samples has been proven to be a useful
marker for diagnosis of iron deficiency and iron deficiency
anemia (IDA) both in children [2–4] and adults [5].
Brugnara et al. [6] demonstrated that CHr also provides
an early measure of the response to parenteral iron therapy
increasing within 2–4 days of the initiation of intravenous
iron therapy.
The goal of therapy for IDA, the most common hema-
tological disease of infancy and childhood, is to supply
sufficient iron to repair the hemoglobin (Hb) deficit and
replenish storage iron [7]. Oral iron administration is a well-
established effective and worldwide accepted treatment for
anemia derived from inadequate dietary iron intake because
of its efficacy, safety, and cost-effectiveness [8]. Thus, in
our Pediatric Hematology Unit, oral iron treatment is the
first-line therapy for all children with IDA with anamnestic
suspicion of inadequate iron intake, independently of base
Hb level. Recently, we have identified absolute reticulocyte
count (ARC) and CHr as accurate and precocious markers
in order to early detect early responders to exclusive oral iron
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therapy in a small cohort of pediatric patients with severe iron
deficiency anemia (IDA) [9]. These preliminary results in
childrenwith very low baseHb levels (medianHb level before
treatment 6.3 g/dL; range 4.5–7.0) prompted us to investigate
the efficacy of reticulocyte parameters in monitoring the
response to oral iron supplementation in a larger cohort of
pediatric patients.
2. Materials and Methods
2.1. Patients and Hematological Evaluation. Clinical records
of patients referred to our Pediatric HematologyUnit for IDA
between July 1, 2012, and June 30, 2014, were retrospectively
analyzed.
Patients who matched inclusion criteria and did not
present exclusion criteria were included in the study. Data
about patients with an age between 6 months and 16 years, a
hemoglobin level more than 2 standard deviations below the
mean reference value for age and gender, a transferrin satu-
ration < 15%, and a high anamnestic suspicion of inadequate
iron intake were analyzed. Patients with diagnosis of celiac
disease, positivity of fecal occult blood test, or positivity of
Helicobacter pylori fecal antigen test were excluded. Patients
from our preliminary report were not included in the present
study [9].
All children with these characteristics had started a first-
line treatment with exclusive oral iron supplementation at
a dosage equivalent to 2mg/kg/die of elemental iron. In all
patients but one, who underwent therapy with liposomial
iron, bisglycinate chelate iron was administered.
Data about Hb levels and reticulocyte parameters (ARC
and CHr) at diagnosis, before treatment (T0), within 7
days (T1), and at day +30 (T2) from the beginning of iron
supplementation, were extrapolated from clinical records of
each patient and analyzed with analytical methods.
Hb and reticulocyte parameters on peripheral blood sam-
ples had been measured with an automated flow cytometer
(Advia 120 Bayer) with optic measure; reticulocytes had
been stained with dye oxazine 750. Approximately 50.000
cells had been counted for each red blood cell and reticulocyte
determinations.
2.2. Statistical Analysis. We described data as number and
frequencies or mean and standard deviation for qualitative
and quantitative variables, respectively.
Differences between different groups of patients were
tested using Fisher’s exact test orWilcoxon sum rank test (due
to the not normal distribution of all the values as established
by means of Shapiro-Wilks normality tests), as appropriate.
To account for possible confounding variables, we per-
formed a multivariate logistic model, adjusting for age, sex,
and Hb value at diagnosis.
Relative increase of ARC and CHr from T0 to T1 was
computed as (T1 value − T0 value)/T0 value.
All tests were two-sided and a 𝑝 value lower than 0.050
was considered significant. Analyses were performed using
SAS V9.4.
2.3. Definitions. Response was defined as early and complete
if patients reached mean Hb reference value for age at day
+30 (T2) from the onset of iron therapy (complete early
responders (CERs)).
Response at T2 was defined as early and partial if patients
reached an Hb concentration at least 50% higher than the
original one, computed as (Hb T2 − Hb T0)/Hb T0 (partial
early responders, PERs).
Patients who at T2 did not achieve an Hb concentration
at least 50% higher than the original one were classified as not
early responders (NERs).
3. Results and Discussion
3.1. Patients. Thirty-four pediatric patients, 22 males and 12
females, with a mean (SD) age at diagnosis of 52 (61) months,
matched inclusion criteria and were enrolled in the study.
Patients’ characteristics at diagnosis are set out in Table 1.
3.2. Hemoglobin and Reticulocyte Parameters at T0, T1, and
T2. Data regarding values of Hb, ARC, and CHr at T0, T1,
and T2 are set out in Table 2.
Mean (SD) Hb level before treatment (T0) was 6.84
(1.22) g/dL. It increased to 7.36 g/L (1.31) and 10.56 g/L (1.62)
at T1 and T2, respectively.
Mean (SD) ARC before treatment (T0) was 72799/mmc
(35155). It increased to 168583/mmc (101196) at T1 and then
decreased again to 76317/mmc (38924) at T2, respectively.
CHr could be fully monitored only for 28 patients. Mean
CHr before treatment was 18.20 pg (2.32). It increased to
21.48 pg (3.04) and 25.43 pg (4.49) at T1 and T2, respectively.
Twenty-four/34 patients (70.5%) were classified as com-
plete early responders (CERs), 4/34 (12%) as partial early
responders (PERs), and the remaining 6 (17.5%) as not early
responders (NERs).
Data about mean Hb, ARC, and CHr at T0, T1, and T2 in
different groups of patients are set out in Tables 3(a) and 3(b).
Trends of mean values of Hb, ARC, and CHr in the
different groups of children are graphically represented in
Figure 1.
3.3. Factors Predictive of Response at Day +30: Comparison
between Complete Early Responders and Other Patients. No
differences were detected regarding gender and hemoglobin
values at diagnosis (T0).
CHr at T0 was significantly higher in CERs than in
remaining patients (19.94 pg versus 16.73 pg; 𝑝 = 0.020).
Analysis of Hb values at T1 revealed no difference
between the two different groups (7.67 g/dL versus 6.63 g/dL,
𝑝 = 0.05).
CHr at T1 was significantly different between CERs and
other patients (22.95 versus 18.41; 𝑝 = 0.001).
Relative increase of CHr from T0 to T1, computed as
(T1 CHr−T0 CHr)/T0 CHr, resulted significantly higher in
CERs than in other patients (0.21 versus 0.11, 𝑝 = 0.042).
Results from multivariate logistic models revealed a
higher probability of being a complete early responder due
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Table 1: Patients’ characteristics at diagnosis.
Patient
(id)
Sex
(M/F)
Age at diagnosis
(months)
Hb T0
(g/dL)
ARC T0
(𝑛/mmc)
CHr T0
(pg)
1 M 9 5.8 82800 15.3
2 M 9 5.5 79800 15.4
3 M 12 5.1 54100 15.4
4 M 48 5.0 82200 15.7
5 M 7 5.7 148100 15.7
6 M 24 4.5 145700 15.8
7 F 24 6.8 89200 16.1
8 F 24 6.1 66700 16.4
9 F 144 7.0 126000 16.7
10 F 96 6.3 92300 16.9
11 F 72 6.3 85400 17.2
12 M 36 7.9 78300 17.5
13 M 48 8.1 94000 18.0
14 M 7 8.7 43700 18.2
15 M 9 6.0 56800 18.2
16 F 36 7.8 69500 18.5
17 F 7 5.8 78000 18.8
18 M 11 9.3 53600 18.8
19 F 8 8.9 15500 19.0
20 F 180 7.4 63500 19.4
21 M 60 7.2 47700 19.7
22 M 192 8.5 40500 20.4
23 M 24 7.4 46600 20.4
24 F 156 6.8 78600 20.5
25 F 180 6.5 56100 20.6
26 M 48 7.9 59700 21.2
27 M 36 8.0 19800 21.8
28 M 4 8.8 57700 24.8
29 M 192 6.3 68000 na
30 M 24 6.7 18600 na
31 M 6 6.3 132000 na
32 M 24 6.0 152000 na
33 M 5 6.8 50000 na
34 F 8 5.5 42000 na
to relative increase of ARC from T0 to T1 [OR (95% CI) =
44.95 (1.54–1311.98); 𝑝 < 0.030] and to CHr at T1 [OR (95%
CI) = 3.18 (1.24–8.17); 𝑝 = 0.016]. Both models were adjusted
by age at diagnosis, sex, and level of Hb at T0.
Differences betweenCERs andother patients are reported
in Table 3(a).
3.4. Factors Predictive of Response at Day +30: Comparison
between Early Responders and Not Early Responders. When
the distinction between early responders and not responders
was taken into account, CHr at T1 was significantly different
in the two groups (22.42 versus 18.07; 𝑝 = 0.001).
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Figure 1: Trends of mean Hb, ARC, and CHr values (𝑦-axis) in
early responding patients (CERs + PERs) and not early responding
patients (NERs) at T0: diagnosis, T1: within 7 days from the
beginning of oral iron supplementation, and T2: at +30 from the
onset of therapy (𝑥-axis).
Relative increase of CHr from T0 to T1, computed as
(T1 CHr − T0 CHr)/T0 CHr, resulted significantly higher,
too (0.22 versus 0.004, 𝑝 = 0.006).
Differences between early responders and not responders
are reported in Table 3(b).
3.5. Discussion. Our data confirm the efficacy of oral iron
administration in promptly improving Hb values in patients
with severe anemia, too.
More than 70% of patients retrospectively enrolled in
the study reached mean hemoglobin (Hb) reference value
for age and gender within one month from the initiation
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Table 2: Hemoglobin and reticulocyte parameters at T0 (before treatment), T1 (within 7 days from the beginning of oral iron), and at T2
(day +30 from the beginning of treatment).
Patient
(id)
T0 Hb
(g/dL)
T1 Hb
(g/dL)
T2 Hb
(g/dL)
T0 ARC
(𝑛/mmc)
T1 ARC
(𝑛/mmc)
T2 ARC
(𝑛/mmc)
T0 CHr
(pg)
T1 CHr
(pg)
T2 CHr
(pg)
1 5.8 6.3 9.1 82800 182200 84200 15.3 21.0 26.0
2 5.5 5.7 8.4 79800 137300 141300 15.4 15.8 19.6
3 5.1 5.9 11.1 54100 99100 44000 15.4 18.7 29.8
4 5.0 4.9 7.0 82200 126300 78900 15.7 16.8 16.4
5 5.7 5.9 8.0 148100 232000 154100 15.7 17.5 17.7
6 4.5 4.5 9.4 145700 209400 122200 15.8 20.5 24.9
7 6.8 7.6 12.9 89200 190000 47400 16.1 21.9 25.2
8 6.1 7.2 13.2 66700 155300 31500 16.4 24.2 30.1
9 7.0 7.2 12.4 126000 201400 106200 16.7 19.9 29.0
10 6.3 7.1 11.8 92300 315000 79400 16.9 22.3 27.2
11 6.3 6.1 7.4 85400 134500 107000 17.2 18.3 19.3
12 7.9 8.1 9.8 78300 110600 66000 17.5 20.8 23.7
13 8.1 8.6 10.5 94000 148200 54300 18.0 23.8 27.6
14 8.7 9.7 9.4 43700 71600 67100 18.2 18.8 18.1
15 6.0 7.0 12.2 56800 108200 60000 18.2 19.7 26.6
16 7.8 7.4 9.5 69500 71500 69500 18.5 19.3 23.6
17 5.8 6.3 12.4 78000 232000 43800 18.8 21.0 31.3
18 9.3 9.1 9.5 53600 84200 148300 18.8 17.7 21.0
19 8.9 9.3 10.5 15500 262500 61900 19.0 25.6 22.5
20 7.4 8.8 10.8 63500 148100 44800 19.4 27.3 27.6
21 7.2 7.2 12.5 47700 155900 71100 19.7 22.7 28.9
22 8.5 8.4 10.5 40500 44600 70100 20.4 25.7 26.2
23 7.4 8.8 10.5 46600 240300 42200 20.4 26.7 32.1
24 6.8 7.7 13.7 78600 105500 26100 20.5 24.3 32.0
25 6.5 8.9 10.7 56100 149900 188500 20.6 22.6 22.3
26 7.9 7.5 10.4 59700 93900 35400 21.2 22.0 26.3
27 8.0 8.9 11.8 19800 42000 63500 21.8 22.9 30.9
28 8.8 9.2 10.8 57700 59200 75500 24.8 23.9 26.2
29 6.3 6.9 10.0 68000 101340 82800 na na na
30 6.7 8.0 10.0 18600 345700 26400 na na na
31 6.3 6.7 12.4 132000 294100 37000 na na na
32 6.0 6.7 9.3 152000 233000 103000 na na na
33 6.8 6.7 9.8 50000 110000 94500 na na na
34 5.5 6.0 11.2 42000 537000 66800 na na na
of treatment, independently from base Hb level. Only a
negligible percentage of children did not reach an Hb con-
centration at least 50% higher than the original after one
month of therapy andwas therefore classified as unresponsive
to therapy. As our patients have not been tested for alpha
and beta thalassemia at diagnosis or during the first month
of therapy, we cannot rule out the possibility that these
children have not responded to iron because of a concomitant
hemoglobinopathy.
Measurement of reticulocyte hemoglobin content (CHr)
has been validated in literature as the strongest independent
predictor of iron deficiency and iron deficiency anemia, when
compared to other laboratory markers (hemoglobin, ferritin,
transferrin saturation, or mean corpuscular volume), both
in children and in adults [1]. In pediatric patients, optimal
CHr cut-off has been proven to be 27.5 pg for detecting iron
deficiency (with a sensitivity of 83% and a specificity of 72%)
[3] and 26 pg for detecting iron deficiency anemia (with a
sensitivity of 83% and a specificity of 75%) [2]. In the totality
of children described in our cohort (all displaying severe iron
deficiency, defined by a transferrin saturation value of less
than 10%), CHr levels were significantly lower than cut-off
level of 26 pg (𝑝 < 0.001 for corresponding Wilcoxon test),
and in 75% of children resulted even less than 20 pg.
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Table 3: Descriptive characteristics of patients, divided into CERs = complete early responders (i.e., normal Hb value at day +30 for therapy
onset), PERs = partial early responders (Hb value at day +30 at least 50% higher than the original one), and NERs = not early responders. 𝑝
values come fromWilcoxon sum rank test.
(a)
CERs (𝑛 = 24) PERs + NERs (𝑛 = 10)
𝑛 (%) 𝑛 (%) 𝑝 value
Male 14 (63.64%) 8 (36.36%) 0.430
Female 10 (83.33%) 2 (16.67%)
Mean (SD) Mean (SD) 𝑝 value
T0 Hb (g/dL) 7.00 (1.03) 6.46 (1.60) 0.134
T1 Hb (g/dL) 7.67 (1.02) 6.63 (1.68) 0.050
T2 Hb (g/dL) 11.33 (1.15) 8.70 (0.94) <0.001
T0 ARC (𝑛/mmc) 63820 (29399) 94280 (39813) 0.040
T1 ARC (𝑛/mmc) 177077 (113504) 148200 (63023) 0.620
T2 ARC (𝑛/mmc) 63300 (33954) 107560 (32749) 0.002
(T1 ARC − T0 ARC)/T0 ARC 2.92 (4.87) 0.58 (0.29) 0.023
T0 CHr (pg) 19.04∗ (2.33) 16.73∘ (1.44) 0.020
T1 CHr (pg) 22.95∗ (2.38) 18.41∘ (1.69) 0.001
T2 CHr (pg) 27.66∗ (2.99) 20.73∘ (3.38) 0.001
(T1 CHr−T0 CHr)/T0 CHr 0.21∗ (0.14) 0.11∘ (0.14) 0.042
∗
𝑛 = 19 ∘𝑛 = 9
(b)
CERs + PERs (𝑛 = 28) NERs (𝑛 = 6)
𝑛 (%) 𝑛 (%) 𝑝 value
Male 18 (81.82%) 4 (18.18%) 1.000
Female 10 (83.33%) 2 (16.67%)
Mean (SD) Mean (SD) 𝑝 value
T0 Hb (g/dL) 6.78 (1.12) 7.13 (1.73) 0.790
T0 Hb (g/dL) 7.40 (1.20) 7.18 (1.90) 0.750
T0 Hb (g/dL) 11.00 (1.35) 8.47 (1.14) 0.001
T0 ARC (𝑛/mmc) 71143 (35210) 80417 (36866) 0.580
T0 ARC (𝑛/mmc) 178991 (105758) 120017 (61270) 0.120
T0 ARC (𝑛/mmc) 70354 (36863) 104150 (39149) 0.040
(T1 ARC−T0 ARC)/T0 ARC 2.60 (4.56) 0.49 (0.23) 0.005
T0 CHr (pg) 18.56∗ (2.49) 17.35∘ (1.39) 0.300
T1 CHr (pg) 22.42∗ (2.73) 18.07∘ (0.91) 0.001
T2 CHr (pg) 27.09∗ (3.30) 19.35∘ (2.60) <0.001
(T1 CHr−T0 CHr)/T0 CHr 0.22∗ (0.14) 0.04∘ (0.06) 0.006
∗
𝑛 = 22
∘
𝑛 = 6
The finding that CHr at T0 was significantly lower in
patients who did not reach normal Hb levels at day +30 raises
the intriguing possibility that CHr level at diagnosis might be
a predictor of early response to oral iron. To our knowledge,
no data about this issue are present in literature to date.Due to
the limitations derived from the small sample size, our results
need to be confirmed on larger cohorts of patients.
As reticulocyte indices allow a real-time evaluation of
iron deficient erythropoiesis and of the effectiveness of iron
replacement therapy [1], CHr has been validated in literature
as an early predictor of response to parenteral iron therapy, in
children receiving hemodialysis [10] and in adults [6].
Similar conclusion regarding response to exclusive oral
iron therapy in a small cohort of children with severe iron
deficiency anemia had been previously reported by our group
[9]. Main outcome of our preliminary study [9] was to
evaluate if oral iron supplementation should be proposed
as first-line treatment in a small cohort of clinically asymp-
tomatic patients with severe iron deficiency anemia. These
patients, due to their Hb levels (median 6.3 g/dL, range
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4.5–7), needed a tight follow-up; for that reason, the kinetic
of response was assessed within 48 hours from the onset
of iron administration (T1) and our data demonstrated the
utility of ARC and CHr as accurate markers for the early
detection of patients not responding to oral iron to be quickly
switched to other therapies (parenteral iron supplementation
or transfusion). These results prompted us to investigate
the efficacy of reticulocyte parameters in monitoring the
response to oral iron supplementation in a larger cohort of
pediatric patients.
Despite the limitations derived from the retrospective
nature of the study, analysis of reticulocyte parameters within
one week from the beginning of therapy confirmed CHr to
predict good early hematologic response to iron supplements
after one week of therapy.
In particular, both CHr levels within 7 days from the
beginning of therapy and the relative increase of CHr fromT0
to T1 resulted significantly higher in patients who displayed
normal hemoglobin levels or a hemoglobin concentration at
least 50% higher than the original one at day +30.
4. Conclusions
Aimof the present studywas to evaluate kinetic of response to
oral iron in a cohort of pediatric patients with iron deficiency
anemia and to investigate the usefulness of reticulocyte
parameters CHr and ARC in monitoring early response to
iron supplementation.
Despite the limitations derived from both the small
number of patients and the retrospective nature of the study,
according to data of literature, our data confirm that oral iron
supplementation is an effective treatment for iron deficiency
anemia, independently from base hemoglobin at diagnosis.
Moreover, our preliminary data suggest that reticulocyte
parameters are early and accurate predictors of response
to oral therapy and that pediatricians could take advantage
of reticulocyte hemoglobin content both at diagnosis and
during follow-up of iron deficiency anemia for assessing early
erythropoietic response to iron replacement therapy.
A prospective multicentre study on a larger cohort of
patients is ongoing in order to reinforce our conclusions.
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